Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 1.00 |
| ▸ | FLT3 | P36888 | 13/20 | 0.79 |
| ▸ | KIT | P10721 | 11/20 | 0.79 |
| ▸ | CSF1R | P07333 | 10/20 | 0.77 |
| ▸ | FLT4 | P35916 | 9/20 | 0.77 |
| ▸ | FLT1 | P17948 | 9/20 | 0.77 |
| ▸ | LYN | P07948 | 8/20 | 0.77 |
| ▸ | SRC | P12931 | 7/20 | 0.77 |
| ▸ | BLK | P51451 | 7/20 | 0.77 |
| ▸ | LCK | P06239 | 7/20 | 0.77 |
| ▸ | FYN | P06241 | 6/20 | 0.77 |
| ▸ | ABL1 | P00519 | 6/20 | 0.63 |
| ▸ | PLK4 | O00444 | 5/20 | 0.61 |
| ▸ | AURKA | O14965 | 5/20 | 0.61 |
| ▸ | MET | P08581 | 5/20 | 0.61 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.61 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.61 |
| ▸ | STK3 | Q13188 | 5/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.61 |
| ▸ | MARK2 | Q7KZI7 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13209956 | 0.89 | KDR (0.80) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL421778 | 0.88 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL2236827 | 0.88 | KDR (0.78) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL1702794 | 0.87 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL12426039 | 0.85 | KDR (0.77) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL421901 | 0.84 | KDR (0.80) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL5337990 | 0.84 | KDR (0.73) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL1702780 | 0.84 | KDR (0.77) | KDRFLT3KITCSF1RFLT4 | |
| Hydrochloric Acid SCHEMBL3959214 | 0.83 | KDR (0.72) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL1703063 | 0.83 | KDR (0.77) | KDRFLT3KITCSF1RFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807424-B1 | NOVEL KINASE INHIBITORS | ABBOTT LAB (US) | 2012-04-18 | — | — | EP | claimed |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | claimed |
| EP-1845978-B1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | claimed |
| CN-101146534-A | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA SA (FR) | 2008-03-19 | — | — | CN | claimed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | claimed |
| EP-1845978-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-24 | — | — | EP | claimed |
| US-20060178378-A1 | Novel kinase inhibitors | ABBVIE INC. | 2006-08-10 | — | — | US | claimed |
| WO-2006077319-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-07-27 | — | — | WO | claimed |
| EP-1807424-B1 | NOVEL KINASE INHIBITORS | ABBOTT LAB (US) | 2012-04-18 | — | — | EP | disclosed |
| US-8008322-B2 | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA S.A. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-8008322-B2 | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA S.A. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-8008322-B2 | Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use | AVENTIS PHARMA S.A. (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A.. (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | disclosed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | disclosed |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2008-02-14 | — | — | US | disclosed |
| EP-1845978-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-24 | — | — | EP | disclosed |
| US-20060178378-A1 | Novel kinase inhibitors | ABBVIE INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006077319-A1 | SUBSTITUTED PYRAZOLO-PYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178378-A1 | Novel kinase inhibitors | ABL1, MAP3K19, MAP3K20 | KDR 434/4885FLT3 79/4885KIT 426/4885 |
| US-20110190337-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | KDR 2947/4885FLT3 121/4885KIT 358/4885 |
| US-20080039491-A1 | SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE | DPYD, TYMP, PCK2 | KDR 2947/4885FLT3 121/4885KIT 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.